Print
Email
SaveHealthline's Premium Tools
Symptom Search
Discover possible causes based on the symptoms you enter. It's fast, convenient and easy to use.
Discover possible causes based on the symptoms you enter. It's fast, convenient and easy to use.
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
... chair ... innocently commanding everyone's attention. Bonnie Goodhart, in an often painful day-to-day battle with chronic lymphocytic leukemia for five years now, finally had something to say. Everyone listened, too. "I just wish there was a way we ...
|
|
For the first time researchers have proved that there is a genetic susceptibility to developing chronic lymphocytic leukaemia , the most common form of leukaemia in the Western world.
|
|
Abstract Leukemia-cell expression of ZAP-70, CD38, or unmutated immunoglobulin heavy chain variable region genes each is associated with aggressive disease in patients with chronic lymphocytic leukemia .
|
|
... cyclophosphamide, and rituximab (FCR) regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia. In this report, we present the final results of all 300 study patients at a median follow up of 6 ...
|
|
Main Category: Lymphoma / Leukemia Also Included In: Cancer / Oncology ; Clinical Trials / Drug Trials Article Date: 27 Aug 2008 - 0:00 PDT Genmab A/S announced plans to begin four studies of ofatumumab in ...
|
|
... drug designation for multiple myeloma (MM) in the EU, US, Australia and Switzerland, and orphan drug designation for chronic lymphocytic leukemia (CLL) in the EU and US. REVLIMID is currently approved for use in the US and Canada for the treatment ...
|
|
... million) was triggered by the achievement of positive results in the Phase III study of ofatumumab in refractory chronic lymphocytic leukemia (CLL). Genmab has received an approximate total of DKK 552 million (approximately USD 110 million) in ...
|
|
... Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial ...
|
|
A Complimentary Continuing Education Monograph VOORHEES, N.J., Aug. 14 /PRNewswire/ -- Chronic lymphocytic leukemia and acute myelogenous leukemia are the two most common types of leukemia diagnosed in adults ...
|
|
... blessing, but this knowledge will help you to work around the issue with maximum effect. One more important thing - leukemia today is not a death sentence by default, like it used to be. We tell that not to give a false hope or over-encourage ...
|
|
Main Category: Lymphoma / Leukemia Also Included In: Pharma Industry / Biotech Industry GlaxoSmithKline and Genmab A/S announced today positive top-line results from an interim analysis of the Phase III pivotal ...
|
|
... M.D., Stephen J. Richards, Ph.D., Andrew S. Jack, Ph.D., and Peter Hillmen, Ph.D. ABSTRACT Background A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic ...
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.